Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the fifteen ratings firms that are currently covering the stock, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $173.07.
A number of research firms have weighed in on JAZZ. The Goldman Sachs Group began coverage on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 5th. They issued a “buy” rating and a $169.00 price objective on the stock. Robert W. Baird cut their price target on Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating for the company in a research note on Thursday, August 1st. Morgan Stanley lowered their price objective on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a research note on Friday, July 12th. Cantor Fitzgerald reiterated an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Finally, StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st.
Read Our Latest Analysis on Jazz Pharmaceuticals
Institutional Inflows and Outflows
Jazz Pharmaceuticals Price Performance
Shares of JAZZ opened at $108.64 on Friday. The business’s fifty day moving average is $109.72 and its 200 day moving average is $112.50. Jazz Pharmaceuticals has a 12-month low of $99.06 and a 12-month high of $143.32. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. The stock has a market cap of $6.85 billion, a P/E ratio of 22.40, a P/E/G ratio of 1.45 and a beta of 0.58.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
See Also
- Five stocks we like better than Jazz Pharmaceuticals
- When to Sell a Stock for Profit or Loss
- Why Dick’s Could Be a Slam Dunk for Your Investment Portfolio
- Dividend Capture Strategy: What You Need to Know
- Introduction to Fibonacci Retracement Levels
- Canada Bond Market Holiday: How to Invest and Trade
- Top 3 Stocks to Outperform the S&P 500 in a Downturn
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.